Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Doria-Rose, Nicole, Suthar, Mehul S., Makowski, Mat, O’Connell, Sarah, McDermott, Adrian B., Flach, Britta, Ledgerwood, Julie E., Mascola, John R., Graham, Barney S., Lin, Bob C., O’Dell, Sijy, Schmidt, Stephen D., Widge, Alicia T., Edara, Venkata-Viswanadh, Anderson, Evan J., Lai, Lilin, Floyd, Katharine, Rouphael, Nadine G., Zarnitsyna, Veronika, Roberts, Paul C., Makhene, Mamodikoe, Buchanan, Wendy, Luke, Catherine J., Beigel, John H., Jackson, Lisa A., Neuzil, Kathleen M., Bennett, Hamilton, Leav, Brett, Albert, Jim, Kunwar, Pratap·2021·New England Journal of Medicine
DOI 10.1056/nejmc2103916

Cited by (646)

Items 201–300 of 646

  1. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern
    Abdul Aziz Al-Fattah Bin Yahaya, Kanwal Khalid, Hui Xuan Lim, Chit Laa Poh · 2023 · Viruses
  2. Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
    Văn Hùng Nguyễn, Catherine Boileau, Alina Bogdanov, Meg Sredl, Mac Bonafede, Thiérry Ducruet, Scott Chavers, Andrew Rosen, David Martin, Philip O. Buck et al. · 2023 · Open Forum Infectious Diseases
  3. One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects
    Jonathan F. Lovell, Kazutoyo Miura, Yeong Ok Baik, Chankyu Lee, Jeong-Yoon Lee, Young-Shin Park, Ingi Hong, Jung Hyuk Lee, Taewoo Kim, Sang Hwan Seo et al. · 2023 · International Journal of Infectious Diseases
  4. Seroconversion After Coronavirus Disease 2019 Vaccination in Patients Awaiting Liver Transplantation: Fact or Fancy?
    Alberto Calleri, Margherita Saracco, Fabrizia Pittaluga, Rossana Cavallo, Renato Romagnoli, Silvia Martini · 2021 · Liver Transplantation
  5. Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients
    Jennifer L. Alejo, Jonathan Mitchell, Teresa Po‐Yu Chiang, Aura T. Abedon, Carolyn N. Sidoti, Brian J. Boyarsky, Robin Kimiko Avery, Aaron A.R. Tobian, Macey L. Levan, Daniel S. Warren et al. · 2021 · Transplantation
  6. Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection
    Blanka Wolszczak-Biedrzycka, Anna Bieńkowska, Justyna Dorf · 2021 · Vaccines
  7. Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
    Takuto Nogimori, Koichiro Suzuki, Yuji Masuta, Mika Yagoto, Mami Ikeda, Yuki Katayama, Ayaka Washizaki, Hidenori Kanda, Minoru Takada, Shohei Minami et al. · 2023 · Frontiers in Immunology
  8. Immunosenescence and Infectious Disease Risk Among Aging Adults
    Deanna Gray‐Miceli, Kathy Gray, Matthew Sorenson, Barbara J. Holtzclaw · 2023 · Advances in Family Practice Nursing
  9. Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses
    Engin Berber, Ted M. Ross · 2024 · Vaccines
  10. Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination
    Maya F. Amjadi, Ryan R. Adyniec, Srishti Gupta, S. Janna Bashar, Aisha M. Mergaert, Katarina M. Braun, Gage K. Moreno, David H. O’Connor, Thomas C. Friedrich, Nasia Safdar et al. · 2022 · The Journal of Infectious Diseases
  11. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers
    Wendy M. Brunner, Daniel Freilich, Jennifer M. Victory, Nicole L. Krupa, Melissa Scribani, Paul Jenkins, Emily G. Lasher, Amanda Fink, Anshini Shah, Peggy Cross et al. · 2022 · International Journal of Infectious Diseases
  12. The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine
    Elizabeth Fraley, Cas LeMaster, Santosh Khanal, Dithi Banerjee, Tomi Pastinen, Elin Grundberg, Rangaraj Selvarangan, Todd Bradley · 2021 · Clinical Infectious Diseases
  13. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
    Stefan Glöckner, Franziska Hornung, Michael Baier, Sebastian Weis, Mathias Wilhelm Pletz, Stefanie Deinhardt‐Emmer, Bettina Löffler, the CoNAN Study Group · 2021 · Viruses
  14. Antibody Dynamics and Durability in Coronavirus Disease-19
    Adam Zuiani, Duane R. Wesemann · 2021 · Clinics in Laboratory Medicine
  15. Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
    Ashley Gray, Rachel Martin‐Blais, Nicole H. Tobin, Yan Wang, Sarah L Brooker, Fan Li, Adva Gadoth, Julie E. Elliott, Emmanuelle Faure-Kumar, Megan Halbrook et al. · 2021 · PLoS ONE
  16. Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases
    Julie J. Paik, Jeffrey A. Sparks, Alfred H.J. Kim · 2022 · Current Opinion in Pharmacology
  17. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
    Sherin Juliet Rouhani, Jovian Yu, Daniel J. Olson, Yuanyuan Zha, Apameh Pezeshk, Alexandra Cabanov, Athalia Rachel Pyzer, Jonathan Trujillo, Benjamin Avi Derman, Peter H. O’Donnell et al. · 2022 · Journal for ImmunoTherapy of Cancer
  18. A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
    Ali Ahmed Rabaan, Abbas Saleh Al Mutair, Khalid Hajissa, Amal H. Alfaraj, Jumana Mansour Al-Jishi, Mashael M. Alhajri, Sara M. Alwarthan, Shahab A. Alsuliman, Amal Hassan Al-Najjar, Ibrahim A. Al-Zaydani et al. · 2022 · Vaccines
  19. Does Physical Exercise Enhance the Immune Response after Vaccination? A Systematic Review for Clinical Indications of COVID-19 Vaccine
    Luca Barni, Elio Carrasco-Vega, Matteo Olivieri, Alejandro Galán-Mercant, Serena Guiducci, Felice Picariello, Manuel González‐Sánchez · 2023 · International Journal of Environmental Research and Public Health
  20. SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
    Thomas E. Hickey, Troy J. Kemp, Jimmie L. Bullock, Aaron J. Bouk, Jordan B. Metz, Abigail Neish, James D. Cherry, Douglas R. Lowy, Lígia A. Pinto · 2023 · Human Vaccines & Immunotherapeutics
  21. Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy
    Giovanni Corrao, Matteo Franchi, Danilo Cereda, Francesco Bortolan, Alberto Zoli, Olivia Leoni, Catia Rosanna Borriello, Giulia Petra Della Valle, Marcello Tirani, Giovanni Pavesi et al. · 2022 · The Lancet Infectious Diseases
  22. A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned
    Megan A. O’Connor, David W. Hawman, Kimberly D. Meade-White, Shanna S. Leventhal, Wenjun Song, Samantha Randall, Jacob F. Archer, Thomas B. Lewis, Brieann Brown, Megan Fredericks et al. · 2023 · PLoS Pathogens
  23. Deaths averted by vaccination due to reduced transmission can exceed those from direct protection of vaccinated individuals for SARS-CoV-2
    Billy J. Gardner, Auston Marm Kilpatrick · 2021 · medRxiv
  24. Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis
    Meggiolaro, Angela, Sane Schepisi, Monica, Farina, Sara, Castagna, Carolina, Mammone, Alessia, Siddu, Andrea, Stefanelli, Paola, Boccia, Stefania, Rezza, Giovanni · 2022 · Expert Review of Vaccines
  25. COVID-19 mRNA vaccines have no effect on endometrial receptivity after euploid embryo transfer
    Pedro Brandão, António Pellicer, Marcos Meseguer, José Remohí, Nicolás Garrido, Juan Antonio García-Velasco · 2022 · Reproductive BioMedicine Online
  26. Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity
    Bart N. Ford, Jonathan B. Savitz · 2022 · Immunity & Ageing
  27. Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
    Naif Khalaf Alharbi, Jaffar A. Al‐Tawfiq, Amal Alwehaibe, Mohammed W. Alenazi, Abdulrahman S. Almasoud, Abdullah A. Algaissi, Fahad Abdulrahman Alhumaydhi, Anwar M. Hashem, Mohammad Bosaeed, Suliman Abdallah Alsagaby · 2022 · Infection and Drug Resistance
  28. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient
    Layan Sukik, Hiam S. Chemaitelly, Houssein H. Ayoub, Peter Valentine Coyle, Patrick Tang, Hadi Mohamad Yassine, Asmaa A. Al Thani, Mohammad R. Hasan, Zaina Al Kanaani, Einas Al‐Kuwari et al. · 2024 · Vaccine
  29. Durability of immune responses to SARS-CoV-2 infection and vaccination
    Mehul S. Suthar · 2024 · Seminars in Immunology
  30. Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine
    Peter Richmond, Lara Hatchuel, Filippo Pacciarini, Branda T. Hu, Igor V. Smolenov, Ping Li, Peng Liang, Htay Htay Han, Joshua G. Liang, Ralf L. Clemens · 2021 · The Journal of Infectious Diseases
  31. Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
    Angelos E. Hatzakis, Andreas Karabinis, Sotirios Roussos, Nikos Pantazis, Dimitrios Degiannis, Antigoni S. Chaidaroglou, Konstantinos Th. Petsios, Ioanna D. Pavlopoulou, Sotirios Tsiodras, Dimitrios N. Paraskevis et al. · 2022 · Vaccines
  32. A Mapping Review on the Uptake of the COVID-19 Vaccine among Adults in Africa Using the 5As Vaccine Taxonomy
    Michael Ebe Kalu, Oluwagbemiga Oyinlola, Michael Chigozie Ibekaku, Israel I. Adandom, Anthony Obinna Iwuagwu, Juliet Chigozie Donatus Ezulike, Ernest C Nwachukwu, Ekezie Mmanwanne Uduonu · 2022 · American Journal of Tropical Medicine and Hygiene
  33. Magnetofluid-Integrated Multicolor Immunochip for Visual Analysis of Neutralizing Antibodies to SARS-CoV-2 Variants
    Haicong Shen, Xinying Chen, Liuqing Zeng, Xing Jun Xu, Yingzhou Tao, Siyin Kang, Yinzhu Lu, Mingjian Lian, Chaoyong James Yang, Zhi Zhu · 2022 · Analytical Chemistry
  34. Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects
    Darin K. Edwards, Andrea Carfı́ · 2022 · Current Opinion in Immunology
  35. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
    Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung The Tran, Siri Mjaaland, Grete Birkeland Kro, Tore Kristian Kvien, David John Warren, Jørgen Jahnsen et al. · 2022 · BMC Medicine
  36. Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant
    Angelia A Eick-Cost, Saixia Ying, Natalie Y. Wells · 2022 · JAMA Network Open
  37. Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity
    Michael Asamoah-Boaheng, David A. Goldfarb, Martin A. Prusinkiewicz, Liam Golding, Mohammad Ehsanul Karim, Vilte Barakauskas, Nechelle Wall, Agatha N. Jassem, Ana Citlali Marquez, Chris MacDonald et al. · 2023 · Cureus
  38. Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination
    Jimmie L. Bullock, Thomas E. Hickey, Troy J. Kemp, Jordan B. Metz, Sarah A. Loftus, Katarzyna Haynesworth, N De Castro, Brian T. Luke, Douglas R. Lowy, Lígia A. Pinto · 2024 · Vaccines
  39. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions
    Michael J. Peluso, Joanna L. Donatelli, Timothy J. Henrich · 2021 · Translational research
  40. A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys
    Prateek Singh, Rajat Ujjainiya, Satyartha Prakash, Salwa Naushin, Viren Sardana, Nitin Bhatheja, Ajay Pratap Singh, Joydeb Barman, Kartik Kumar, Saurabh Gayali et al. · 2022 · Computers in Biology and Medicine
  41. Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
    Douglas F. Lake, Alexa J. Roeder, María J. González‐Moa, Megan A. Koehler, Erin J. Kaleta, Paniz Jasbi, John Vanderhoof, Davis McKechnie, Jack Forman, Baylee A. Edwards et al. · 2022 · Communications Medicine
  42. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
    Eloísa Bonfá, clovis da silva, Ana Medeiros-Ribeiro, Léonard de Vinci Kanda Kupa, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Carla Saad, Solange Regina Giglioli Fusco, Rosa Pereira, Samuel Katsuyuki Shinjo et al. · 2022 · Nature Communications
  43. Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming
    Zhe Zhang, Shipo Wu, Yawei Liu, Kailiang Li, Pengfei Fan, Xiaohong Song, Yudong Wang, Zhenghao Zhao, Xianwei Zhang, Jin Shang et al. · 2022 · medRxiv
  44. Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
    Gonzalo Pérez Marc, Damián Álvarez-Paggi, Fernando P. Polack · 2021 · Journal of Clinical Investigation
  45. Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
    Chin-Shern Lau, Soon Kieng Phua, Ya-Li Liang, Helen May‐Lin Oh, Tar Choon Aw · 2021 · Vaccines
  46. Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination
    Samuel David Stampfer, Marissa‐Skye Goldwater, Sean Elliott Bujarski, Bernard Sean S. Regidor, Wenjuan Zhang, Aaron J. Feinstein, Regina A. Swift, Shahrooz Eshaghian, Eric Vail, James R. Berenson · 2021 · Clinical Infection in Practice
  47. Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients
    Zhe Zhang, Shipo Wu, Yawei Liu, Kailiang Li, Pengfei Fan, Xiaohong Song, Yudong Wang, Zhenghao Zhao, Xianwei Zhang, Jin Shang et al. · 2023 · Frontiers in Immunology
  48. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration
    Chloé Dimeglio, Fabrice Hérin, Isabelle Da-Silva, Marion Porcheron, Guillaume Martin‐Blondel, Sabine Chapuy‐Regaud, Jacques Izopet · 2021 · Clinical Infectious Diseases
  49. IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study
    Louise J. Robertson, Ruth K. Price, Julie S. Moore, Grace Curry, John Farnan, Amy Black, Kevin Blighe, M. Andrew Nesbit, James A. McLaughlin, Tara Moore · 2022 · Vaccine
  50. Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose
    Alessandra Mangia, Nicola Serra, Giovanna Cocomazzi, Vincenzo Giambra, Stefano Antinucci, Alberto Maiorana, Francesco Giuliani, Emanuele Montomoli, Paolo Cantaloni, Alessandro Manenti et al. · 2022 · Frontiers in Public Health
  51. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination
    Pinja Jalkanen, Pekka Kolehmainen, Anu Haveri, Moona Huttunen, Larissa Laine, Pamela Österlund, Paula A. Tähtinen, Lauri Ivaska, Sari Maljanen, Arttu Reinholm et al. · 2022 · Microbiology Spectrum
  52. Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds
    Maxence Meyer, Florentin Constancias, Claudia Worth, Anita Meyer, Marion Müller, Alexandre Boussuge, Georges Kaltenbach, Elise Schmitt, Saïd Chayer, Aurélie Velay et al. · 2022 · GeroScience
  53. The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19
    Małgorzata Łysek-Gładysińska, Magdalena Starz, Agnieszka Borowiec-Sęk, Iwona Sufin, Anna Wieczorek, Magdalena Chrapek, Dorota Zarębska‐Michaluk, Patrycja Sufin, Stanisław Głuszek, Wioletta Adamus-Białek · 2023 · Journal of Inflammation Research
  54. Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times
    Thomas Bachelet, Jean-Philippe Bourdenx, C Martinez, Simon Mucha, Philippe Martin-Dupont, Valerie Perier, Antoine Pommereau · 2021 · PLoS ONE
  55. Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
    Alessio Alesci, Marco Gitto, Magdalena Kotańska, Patrizia Lo Cascio, Anthea Miller, Noemi Nicosia, Angelo Fumia, Simona Pergolizzi · 2022 · Human Immunology
  56. Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines
    Wei J. Chen, Kristin R. Tompkins, Ian W. Windsor, Lyndsey T. Martinez, Minah Ramos, Weiqiang Li, Shikha Shrivastava, Swati Rajput, Jeanne S. Chang, Parag V. Sahasrabudhe et al. · 2025 · Nature Communications
  57. Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
    Giovanna Cocomazzi, Valeria Piazzolla, Maria Maddalena Squillante, Stefano Antinucci, Vincenzo Giambra, Francesco Giuliani, Alberto Maiorana, Nicola Serra, Alessandra Mangia · 2021 · Vaccines
  58. COVID-19 Risk Assessment for the Tokyo Olympic Games
    Wenhui Zhu, Jie Feng, Cheng Li, Huimin Wang, Yang Zhong, Lijun Jane Zhou, Xingyu Zhang, Tao Zhang · 2021 · Frontiers in Public Health
  59. SIRVVD model-based verification of the effect of first and second doses of COVID-19/SARS-CoV-2 vaccination in Japan
    Yuto Omae, Yohei Kakimoto, M. Sasaki, Jun Toyotani, Kazuyuki Hara, Yasuhiro Gon, Hirotaka Takahashi · 2021 · Mathematical Biosciences & Engineering
  60. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses
    Adam V. Wisnewski, Jian Liu, Carolina Gonçalves de Oliveira Lucas, Jon Klein, Akiko Iwasaki, Linda F. Cantley, Louis E. Fazen, Julian Campillo Luna, Martin D. Slade, Carrie A. Redlich · 2022 · PLoS ONE
  61. Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
    Merryn Voysey, Amy L. Flaxman, Jeremy Aboagye, Parvinder K. Aley, Sandra Belij‐Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Sue Charlton, Elizabeth Clutterbuck et al. · 2023 · Clinical & Experimental Immunology
  62. Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination
    Ellie Taus, Christian Hofmann, Francisco Javier Ibarrondo, Laura S. Gong, Mary Ann Hausner, Jennifer A. Fulcher, Paul A Krogstad, Scott G. Kitchen, Kathie G. Ferbas, Nicole H. Tobin et al. · 2023 · Frontiers in Immunology
  63. Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV)
    Marc Germain, Antoine Lewin, Renée Bazin, Mélanie Dieudé, Josée Perreault, Amélie Boivin, Yves Grégoire, Christian Renaud · 2023 · BMJ Open
  64. Machine-learning-aided multiplexed nanoplasmonic biosensor for COVID-19 population immunity profiling
    Aidana Beisenova, Wihan Adi, S. Janna Bashar, Monniiesh Velmurugan, Kenzie B. Germanson, Miriam A. Shelef, Filiz Yesilköy · 2023 · Sensors & Diagnostics
  65. Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination
    Namhee Kim, Dohsik Minn, Seungman Park, Eun Youn Roh, Jong Hyun Yoon, Hyunwoong Park, Sue Shin · 2021 · Journal of Korean Medical Science
  66. The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals
    Yvelise Barrios, Andrés Franco, Inmaculada Sánchez‐Machín, Paloma Poza Guedes, Ruperto González‐Pérez, Victor M. Matheu · 2021 · Vaccines
  67. Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
    René Clavero, Alfredo Parra-Lucares, Gabriel Méndez-Valdés, Eduardo Villa, Karin Bravo, Evelyn Mondaca, Josseline Aranda, Rose Brignardello, Cynthia Gajardo, Angelica Ordenes et al. · 2022 · Vaccines
  68. IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study
    Sergio Gil-Manso, Roberto Alonso, Pilar Catalán, Ignacio Sánchez-Arcilla, Marco Marzola, Rafael Correa‐Rocha, Marjorie Pion, Patricia Muñóz, Gregorio Marañón Microbiology-ID COVID-19 Study Group · 2022 · Frontiers in Cellular and Infection Microbiology
  69. Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics
    J Zhang · 2024 · Heliyon
  70. Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine
    Jiao Wei, Ai‐Min Hui · 2022 · Life
  71. Induction of humoral and cellular immune responses to COVID‐19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers
    Maria H. Nikolova, Yana Todorova, Radoslava Emilova, Iva Trifonova, Teodora Gladnishka, Nina Petrova‐Yancheva, Tatyana P. Chervenyakova, Elena Dragusheva, Georgi T. Popov, Iva Christova · 2022 · Journal of Medical Virology
  72. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
    Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Monprach Harnphadungkit, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda · 2022 · Human Vaccines & Immunotherapeutics
  73. Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines
    Mohammad Reza Sepand, Banafsheh Bigdelou, Jim Q. Ho, Mohammad Sharaf, Alexis J. Lannigan, Ian M. Sullivan, Alecsander P. da Silva, Leland O. Barrett, Scott McGoldrick, Yuvraj Lnu et al. · 2022 · Antibodies
  74. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
    Thierry Burnouf, Birgit Sybille Gathof, Evan M. Bloch, Renée Bazin, Vincenzo De Angelis, Gopal Kumar Patidar, Rada M. Grubovic Rastvorceva, Adaeze Chidinma Oreh, Ruchika Goel, Naomi Rahimi‐Levene et al. · 2022 · Transfusion Medicine Reviews
  75. Blood and saliva SARS-CoV-2 antibody levels in self-collected dried spot samples
    Laura Lahdentausta, Anne S. Kivimäki, Lotta‐Maria Oksanen, Marika Tallgren, Sampo A. Oksanen, Enni Sanmark, Aino Salminen, Ahmed Geneid, Mikko Sairanen, Susanna Paju et al. · 2022 · Medical Microbiology and Immunology
  76. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19
    Philipe Gobeil, Stéphane Pillet, Iohann Boulay, Nathalie Charland, Aurélien Lorin, Matthew Pellan Cheng, Donald Cuong Vinh, Philippe Boutet, Robbert G. Van der Most, François P. Roman et al. · 2022 · Nature Communications
  77. Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose
    Luca Perico, Marta Todeschini, Federica Casiraghi, Marilena Mister, Anna Pezzotta, Tobia Peracchi, Susanna Tomasoni, Piera Trionfini, Ariela Benigni, Giuseppe Remuzzi · 2023 · Frontiers in Immunology
  78. Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up
    André Luiz Loureiro Weigert, Marie‐Louise Bergman, Lígia Antunes Gonçalves, Iolanda Godinho, Nádia Duarte, Rita Abrantes, Patrícia Borges, Ana Brennand, Vanessa Malheiro, Paula Matoso et al. · 2021 · Frontiers in Medicine
  79. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany
    Alex Dulovic, Barbora Kessel, Manuela Harries, Matthias Becker, Julia Ortmann, Johanna Griesbaum, Jennifer Juengling, Daniel Junker, Pilar Hernández, Daniela Gornyk et al. · 2022 · Frontiers in Immunology
  80. Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study
    Hakan Demırhındı, Burak Mete, Ferdi Tanır, Ertan Kara, Filiz Kibar, Sali̇h Çeti̇ner, Aslıhan Candevir, Sukriye Ece Akti · 2022 · Vaccines
  81. Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans
    Mariem Gdoura, Fatma Ben Ghaloum, M. Ben Hamida, Wafa Chamsa, Henda Triki, Chokri Bahloul · 2022 · Scientific Reports
  82. Clinical Development of mRNA Vaccines: Challenges and Opportunities
    Allison August, Luis Brito, Robert Paris, Tal Z. Zaks · 2022 · Current topics in microbiology and immunology
  83. Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people
    Helen Parry, Rachel K. Bruton, Reni Ayodele, Penny Sylla, Graham McIlroy, Nicola A. Logan, Sam Scott, Sam Nicol, Kriti Verma, Christine Stephens et al. · 2022 · Cell Reports Medicine
  84. Technology-assisted adaptive recruitment strategy for a large nation-wide COVID-19 vaccine immunogenicity study in Brunei
    Chin Yee Shim, Si Yee Chan, Yuan Wei, Hazim Ghani, Liyana Ahmad, Hanisah Sharif, Mohammad Fathi Alikhan, Saifuddien Haji Bagol, Surita Taib, Chee Wah Tan et al. · 2022 · Frontiers in Public Health
  85. Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults
    Oladayo Ayobami Oyebanji, Eleftherios E Mylonakis, David H. Canaday · 2022 · Infectious Disease Clinics of North America
  86. Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy
    Jennifer Serwanga, Claire Baine, Susan Mugaba, Violet Ankunda, Betty Oliver Auma, Gerald Kevin Oluka, Laban Kato, Isaac Kitabye, Jackson Sembera, Geoffrey Odoch et al. · 2023 · Frontiers in Immunology
  87. The changing health impact of vaccines in the COVID-19 pandemic: A modeling study
    Jamie A. Cohen, Robyn M. Stuart, Jasmina Panovska‐Griffiths, Edinah Mudimu, Romesh Abeysuriya, Cliff C. Kerr, Michael Famulare, Daniel J. Klein · 2023 · Cell Reports
  88. Challenges to the Effectiveness and Immunogenicity of COVID-19 Vaccines: A Narrative Review with a Systematic Approach
    Alexander A. Soldatov, Nickolay A. Kryuchkov, Горенков Дмитрий Витальевич, Ж. И. Авдеева, О. А. Свитич, Sergey S Soshnikov · 2025 · Vaccines
  89. Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers
    Pablo Knobel, Cònsol Serra, Santiago Grau, Rocio Ibañez, Pilar Díaz, Olivia Ferrández, Rocío Villar, Alonso Fernando Lopez, Nuria Pujolar Fulquet, Juan Pablo Horcajada et al. · 2021 · Infection Control and Hospital Epidemiology
  90. COVID‐19 vaccines: what do we know so far?
    Paraminder Dhillon, Daniel Martin Altmann, Victoria H. Male · 2021 · FEBS Journal
  91. Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
    Sarah M. Frey, Caoilfhionn Marie Connolly, Teresa Po‐Yu Chiang, Mayan S. Teles, Jennifer L. Alejo, Brian J. Boyarsky, Lisa Christopher‐Stine, William A. Werbel, Dorry Lidor Segev, Julie J. Paik · 2021 · The Lancet Rheumatology
  92. Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022
    Kevin J. Downes, Victoria A. Statler, Rachel C. Orscheln, Melissa K. Cousino, Michael Green, Marian G. Michaels, William J. Muller, Tanvi S. Sharma, Lara A. Danziger‐Isakov, Monica I. Ardura · 2021 · Journal of the Pediatric Infectious Diseases Society
  93. Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
    Robert Flisiak, Małgorzata Pawłowska, Magdalena Rogalska, Monika Bociąga‐Jasik, Krzysztof Kłos, Anna Piekarska, Dorota Zarębska‐Michaluk · 2021 · Vaccines
  94. Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations
    Sanjay K. Murthy, M Ellen Kuenzig, Joseph W. Windsor, Jean‐Eric Ghia, Anne Marie Griffiths, Remo Panaccione, Cynthia H. Seow, Eric Ian Benchimol, Charles Noah Bernstein, Alain Bitton et al. · 2021 · Journal of the Canadian Association of Gastroenterology
  95. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
  96. Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population
    Javeria Aijaz, Shakir Hussain, Fouzia Naseer, Fatima Kanani, Sabiha Anis, Samreen Sarfaraz, Saima Saeed, Hina Farooq, Saba Jamal · 2022 · Vaccines
  97. Lasting SARS-CoV-2 specific IgG Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V
    Franklin Claro, Douglas Silva, Jesús A. Pérez Bogado, Hector Rafael Rangel, Jacobus Henri de Waard · 2022 · International Journal of Infectious Diseases
  98. Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection
    Loukia Psaridi, Helena C. Maltezou, Sofia Simonidou, Ioanna Lialliou, Despina Athanasopoulou, Zoi Haila, Areti Kyrimi, Ioanna Giannopoulou, Styliani Giannousa, Maria Pseimada et al. · 2022 · Vaccine
  99. Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2
    Maria Agallou, Olga S. Koutsoni, Maria Michail, Paraskevi Zisimopoulou, Ourania Tsitsilonis, Evdokia Karagouni · 2022 · The Journal of Infectious Diseases
  100. Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
    Lei Wang, Zhiwei Wu, Zhifang Ying, Minjie Li, Yuansheng Hu, Qun Shu, Jing Li, Huixian Wang, Hengming Zhang, Wenbin Jiao et al. · 2022 · Nature Communications